Sivakkanan Loganathan

Sivakkanan Loganathan

Auto-generated profile, based on publicly available information

Sivakkanan Loganathan

Experimentelle Herzchirurgie

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
SLSivakkanan Loganathan
Sivakkanan Loganathan
TRTamás Radovits
Tamás Radovits
KHKristóf Hirschberg
Kristóf Hirschberg
SKSevil Korkmaz
Sevil Korkmaz
AKAchim Koch
Achim Koch
GSGábor Szabó
Gábor Szabó

30 June 2009 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
KHKristof Hirschberg
Kristof Hirschberg
TRTamás Radovits
Tamás Radovits
SLSivakkanan Loganathan
Sivakkanan Loganathan
LELászló Entz
László Entz
CBCarsten J. Beller
Carsten J. Beller
GSGábor Szabó
Gábor Szabó

17 January 2012 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
SLSivakkanan Loganathan
Sivakkanan Loganathan
TRTamás Radovits
Tamás Radovits
SKSevil Korkmaz-Icöz
Sevil Korkmaz-Icöz
KHKristof Hirschberg
Kristof Hirschberg
EBEnikö Barnucz
Enikö Barnucz
GSGábor Szabó
Gábor Szabó
Background Recent studies have shown the potential of PDE-5 inhibition on acute and chronic heart failure. Nevertheless it remained unclear, how far load-reducing properties and direct effects on myocardial contractility are responsible for these observations. In the present study, we investigated the effects of vardenafil on myocardial contractility and vascular function in a dose–response study. Methods We performed left ventricular pressure-volume analysis in young adult rats by using a Millar microtip conductance catheter. Pressure-volume loops were recorded before and after intravenous injection of vardenafil (3, 10, 30, 100, 300 μg/kg, n = 6/group). Results Treatment with vardenafil resulted in a significant (p < 0.05) increase in the load-independent cardiac contractility parameters reaching its maximum at the dose of 100μg/kg (ESPVR: 2.15 ± 0.15 vs. 3.29 ± 0.26 mm Hg/μL; PRSW: 93.28 ± 4.04 vs. 134.90 ± 6.27 mm Hg; peak positive dP/dt/EDV: 38.73 ± 7.97 vs. 53.02 ± 3.74 mm Hg·s−1·µL−1; before versus after 100 μg/kg vardenafil). Results of the in vitro organ-bath experiments showed an augmented vasorelaxation of precontracted aortic rings after vardenafil treatment. Conclusion Our data supports the hypothesis that the usage of vardenafil as “inodilators” could have beneficial effects in heart failure patients.

13 May 2012 in Zeitschrift für Herz-,Thorax- und Gefäßchirurgie
Verified
Journal Article
Closed access
PDF file
SLS. Loganathan
S. Loganathan
SKS. Korkmaz
S. Korkmaz
TRT. Radovits
T. Radovits
KHK. Hirschberg
K. Hirschberg
EBE. Barucz
E. Barucz
GSG. Szabo
G. Szabo

11 August 2009 in BMC Pharmacology
Verified
Journal Article
Open access
PDF file
SLSivakkanan Loganathan
Sivakkanan Loganathan
TRTamás Radovits
Tamás Radovits
KHKristóf Hirschberg
Kristóf Hirschberg
SKSevil Korkmaz
Sevil Korkmaz
MKMatthias Karck
Matthias Karck
GSGábor Szabó
Gábor Szabó